BroadOak Capital Partners

Congratulations to Werner, Hudson Robotics, Inc. and Argosy Healthcare Partners on this excellent news!

Meeting on the Mesa is a premier Cell and Gene Therapy event bringing together innovators and investors to preview challenges and opportunities in the space. BroadOak's Dan Friedman attended this year's conference and connected with industry leaders solving critical problems to enable CGT to become a household name. #MeetingOnTheMesa #CGT #CGMewsa24 #Biotools

We are pleased to share that BroadOak Capital Partners advised Omixon on its sale of the company to Werfen.? ? Omixon, a privately held company based in Budapest, Hungary, develops and commercializes NGS technology for transplant diagnostics. ? Read the full announcement:?https://lnkd.in/ePgp8PnY

LabConnect is pleased to announce the appointment of?Wesley P. Wheeler to serve as its Chief Executive Officer and member of the Board of Directors.?Wes brings over two decades of leadership experience and a proven track record of delivering growth and operational excellence across multiple high-profile companies within the pharmaceutical services industry. With a wealth of expertise, having served as CEO/President of five different companies, Wes is well-equipped to lead LabConnect through its next phase of growth and international expansion. His appointment signals a strategic move as the company continues its upward trajectory in delivering innovative central lab services to a global clientele. Read full press release at https://lnkd.in/gq3bT53c

We're pleased to welcome Royal Donigan as an analyst on BroadOak Capital Partners's advisory team where he'll provide M&A transaction support. Royal's experience managing and executing transactions for a global investment banking firm, completing over $2 billion in sell-side transactions, will help grow BroadOak's advisory services presence. Join us in welcoming Royal! #Mergers #Acquisitions #BroadOak #NewHire #LifeScience

We are proud that PitchBook has named BroadOak Capital Partners the second-most active investor in the pharma services industry. In a recent interview, BroadOak Managing Director Michael Caspani commented on broader trends redirecting capital flows towards pharma services: “There are good tailwinds surrounding this sector for a few reasons… The National Institutes of Health has a consistent funding track record, which is highly correlated to a steady pipeline of small businesses that need growth capital. The companies we invest in provide the tools and services in the drug development process and they are characterized as having non-binary risk, as their success is not hinged on the FDA’s approval of a drug,” Read the full story. https://lnkd.in/eJAbZurM #PharmaServices #LifeSciences #Pitchbook #BroadOak #LifeScienceTools

We're excited to welcome Elliot Frumkin as BroadOak Capital Partners' Director of Investor Relations. Elliot's deep experience engaging investors and forming long-lasting relationships with key stakeholders will enable BroadOak Capital Partners to continue to grow and scale. At BroadOak, we believe in putting our investors first, and we know that trust and communication are the foundation of any successful relationship. Please join us in welcoming Elliot Frumkin to the team! #BroadOak #NewHire #LifeScience #Investors #InvestorRelations

BroadOak's Austin Duke participated in several panels and workshops to kick off the 2024 BioTools Innovator Summit.? ? BioTools Innovator was established to improve human health by accelerating the growth of a broad spectrum of life science tools and diagnostics. BioTools Innovator matches industry leaders with innovative early stage and emerging growth biotechnology-focused companies for mentorship and support. ? BroadOak Capital Partners is proud to be a founding sponsor of BioTools Innovator, and we're excited to provide mentorship and support to the 2024 Cohort as they pioneer new?biotech solutions. ? #BroadOakCapitalPartners #InnovatorSummit2024 #lifesciencetools #biotools #techbio #BTI

Congratulations?to PAK BioSolutions, a portfolio company of BroadOak’s BioTools Venture Fund, on their recent raise to expand commercial and product development. This financing validates all the great work that Joanna, Kevin, and their team have accomplished, as well as the exciting market opportunity for continuous manufacture of biologics. #biologics #investment #BioToolsVentureFund #BroadOak

We're proud to sponsor?BioTools Innovator, which brings together entrepreneurs, industry leaders, and investors. This year's competition features 20 companies working to create revolutionary biotech products. Learn more about the 2024 BioTools Innovator Cohort?https://lnkd.in/giF4HCi4 #BTI #BioToolsInnovator #Biotech #LifeScience #Biotools